Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 19/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867154 | 0.85 | DPP4 (0.34) | PREPDPP4DPP8DPP9 | |
| SCHEMBL17913615 | 0.80 | — | — | |
| SCHEMBL21986229 | 0.80 | DPP4 (0.43) | PREPDPP4DPP8DPP9 | |
| SCHEMBL28056504 | 0.77 | DPP4 (0.46) | PREPDPP4 | |
| SCHEMBL5140895 | 0.76 | DPP4 (0.47) | PREPDPP4 | |
| SCHEMBL2605419 | 0.75 | — | — | |
| SCHEMBL4434550 | 0.75 | — | — | |
| SCHEMBL15238182 | 0.75 | — | — | |
| SCHEMBL28834183 | 0.74 | DPP4 (0.48) | DPP4 | |
| SCHEMBL15639189 | 0.74 | DPP4 (0.47) | PREPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178575-B2 | Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase IV | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-05-15 | — | — | US | disclosed |
| US-20100016314-A1 | DERIVATIVES OF AZABICYCLO OCTANE, THE METHOD OF MAKING THEM AND THE USES THEREOF AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| EP-2133077-A1 | DERIVATIVES OF AZABICYCLO OCTANE, THE METHOD OF MAKING THEM AND THE USES THEREOF AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016314-A1 | DERIVATIVES OF AZABICYCLO OCTANE, THE METHOD OF MAKING THEM AND THE USES THEREOF AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | DPP4, DPP3, DPP8 | PREP 21/4885DPP4 1/4885DPP8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.